Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus FOLFIRI versus placebo plus FOLFIRI in second-line metastatic colorectal cancer
2012-000709-59Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in metastatic colorectal adenocarcinoma (mCRC) comparing Regorafenib + FOLFIRI with Placebo + FOLFIRI (2 arms). Primary endpoint: Progression-free survival. Started Mar 2012; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2012-000709-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000709-59.